強
強気
強気 · 25%AZN
$82.29
シナリオ価格
$168.820
+5.014 (+2.97%)終値時点
Loading chart…
- 高値
- 169.235
- 始値
- 166.770
- 出来高加重平均価格
- 168.24
- 出来高
- 4.08M
- 時価総額
- 242.40B
- 安値
- 166.660
- 売買代金
- 686.94M
- EV/EBITDA（TTM）
- 12.80
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
AI分析 of AstraZeneca PLC (AZN)
買いAstraZeneca is a good buy right now, trading at $165.41 with a forward P/E of 14.62, suggesting it is undervalued compared to its growth potential. The RSI is at 65.38, indicating bullish momentum, while the recent strategic collaboration with insitro could drive future revenue growth. The main risk is the year-to-date decline of 9.45%, reflecting market concerns that could impact short-term performance.
アナリスト評価（5）
上値余地 +26.55%
買い
4 買い
1 中立
0 売り
現在: 168.82
安値
157.61
平均
213.64
高値
252.18
Citi
買い
—
2026-10-06
Citi
2026-10-06
目標株価
—
買い
Berenberg
買い
—
2026-09-15
Berenberg
2026-09-15
目標株価
—
買い
Deutsche Bank
中立
—
2026-09-15
Deutsche Bank
2026-09-15
目標株価
—
中立
HSBC
中立
—
2026-09-10
HSBC
2026-09-10
目標株価
—
中立
RBC Capital
アウトパフォーム
—
2026-09-08
RBC Capital
2026-09-08
目標株価
—
アウトパフォーム
バリュエーション指標
AstraZeneca PLC（AZN）の現在の予想PERは14.62で、5年平均は16.39です。
Alphio AI による AZN の価格シナリオ
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト（25 / 50 / 25）であり、保証ではありません。
AZN を保有するクジラ
イベントタイムライン
ニュース
2.010-19stocktwitsSellas Life Sciences Faces Pressure on Regal Trial Results Ahead of ASH
7.510-17stocktwitsGilead Partners with Vir to Develop Cancer Drugs
7.510-15stocktwitsAstraZeneca Enters Strategic Collaboration with insitro for Drug Discovery
8.510-12stocktwitsSellas Life Sciences Shares Rise 3% Amid ASH Meeting Speculation
9.510-10CNBCBank of America Sees Strong Buying Opportunities Ahead of Q3 Earnings
AZN のよくある質問 — Alphio AI が回答
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
AstraZeneca is a good buy right now, trading at $165.41 with a forward P/E of 14.62, suggesting it is undervalued compared to its growth potential. The RSI is at 65.38, indicating bullish momentum, while the recent strategic collaboration with insitro could drive future revenue growth. The main risk is the year-to-date decline of 9.45%, reflecting market concerns that could impact short-term performance.
5 analysts cover AZN: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 213.64.
コミュニティ
もっと見る ↗
AstraZeneca and Oracle launch global AI collaboration to advance clinical trial optimisation and support better patient outcomes Partnership aims to advance solutions to improve care pathways, clinical trial matching, safety monitoring, and guideline-directed care AstraZeneca and Oracle Health and Life Sciences today announced a unique collaboration to leverage AstraZeneca's scientific, clinical development and regulatory expertise with Oracle's real-world data, cloud infrastructure, and AI-enabled clinical capabilities to accelerate clinical research and bring evidence-driven insights into care workflows to accelerate clinical trial optimisation and help more patients receive the right care sooner. $AZN $ORCL
もっと見る
$SMMT just landed a major combo opportunity for ivonescimab — and Datroway is the key. Summit is teaming with AstraZeneca ($AZN) and Daiichi Sankyo to evaluate ivonescimab with Datroway, a TROP2-targeted ADC jointly developed and commercialized by Daiichi and AstraZeneca. The initial focus is a Phase III study in first-line TNBC, while the collaboration plans to evaluate the combo across multiple solid tumors, including breast and lung cancers. Latest SMMT news here
もっと見る
$SMMT $AZN Citi raised its price target on Summit Therapeutics (SMMT) to $43 from $40 and keeps a Buy rating on the shares after the company announced a $2B investment from AstraZeneca (AZN). AstraZeneca's $2B investment in convertible preferred shares is equivalent to $18.36 per common share, representing a 19% premium to Summit's latest closing price, the analyst tells investors in a research note. Citi views the deal as a "de-risking event" that removes Summit's financing overhang.
もっと見る
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。